Think Bioscience
Develops small molecule drugs for historically challenging drug targets
$55MSeries A
Role not disclosedYB
YK Bioventures
Activity from announced rounds
Activity in this selectionJan 31, 2026 · Jan 1, 2026
YK Bioventures is the life-sciences venture firm whose own profile identifies Think Bio, Vivere, Moonwalk and Tempo.
Recorded funding activity
Think develops small-molecule medicines. Moonwalk targets fat-tissue pathways, while Tempo develops regenerative scaffolds. These programs pursue distinct therapeutic mechanisms within the recorded activity.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $65M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionVivere Oncotherapies
Vivere Oncotherapies develops cancer treatments designed to activate immune recognition and destruction of cancer cells.
$10MSeries A
Role not disclosed